PriceSensitive

Plurilock (TSXV:PLUR) secures order with U.S. pharmaceutical manufacturer

Technology
TSXV:PLUR
28 May 2021 09:00 (EDT)
Plurilock - CEO, Ian Paterson.

Source: Plurilock.

Plurilock Security (PLUR) has secured an order through GiaSpace to license its authentication software to a regional pharmaceutical manufacturer in the U.S.

The order includes deployment and support for Plurilock’s high margin ADAPT and DEFEND products at the manufacturer’s facilities.

Recent data shows that healthcare organizations are more susceptible to attacks amidst the COVID-19 pandemic. Research also shows that one in ten global pharmaceutical manufacturers are at high risk for a ransomware attack.

“Plurilock’s high margin software solutions work as a deterrence to attacks and form part of an in-depth defensive cybersecurity strategy, crucial to companies operating today,” said Ian L. Paterson, CEO of Plurilock.

“Modern-day ransomware is more sophisticated than ever, and these skilled adversaries are finding ways to penetrate networks, identify high-value targets, and access critical information before detonating an attack on systems, causing significant damage and downtime for organizations. With the deployment of Plurilock’s authentication software, these organizations will be able to protect the workforce as well as other critical assets against cyberattacks.”

Plurilock’s proprietary technology has the ability to recognize individuals and verify identities using behavioural biometric signatures as device users do their normal work, which will be beneficial for organizations in the pharmaceutical industry.

Plurilock’s world-class cybersecurity solutions paired with AI-driven, cloud-friendly security technologies deliver persistent identity assurance with unmatched ease of use. The Plurilock family of companies enables organizations to operate safely and securely while reducing cybersecurity friction.

Plurilock Security Inc. (PLUR) opened trading at C$0.53 per share.

Related News